PCI BIOTECH ASA NK 3(4QG)

Description: PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company's technology platform consists of a proprietary small molecule photosensitiser (fimaporfin) and a light source; and develops photochemical internalisation (PCI), inducing light-triggered intracellular release for various therapeutic modalities, as well as photochemical lysis (PCL) comprising light-triggered cell lysis, which enhances yield and purity in viral vector manufacturing. It also explores for intratumoural immunotherapy therapeutics that identifies novel treatment combinations to overcome resistance to immune-checkpoint inhibitors and safety-issues associated with treatments; and develops nucleic acid therapeutics to improve the treatment of dermatological diseases. In addition, the company develops fimaVACC for immunotherapy indications, which is in pre-clinical study; fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study for bioprocessing and dermatology indications; and technology for viral vector manufacturing and pre-clinical research for intratumoural immunotherapy. PCI Biotech Holding ASA was incorporated in 2007 and is headquartered in Oslo, Norway.

---

Keywords: Cancer Biopharmaceutical Treatment Of Cancer Immunotherapy Gene Therapy Virotherapy Gene Delivery Bioprocessing Molecular Genetics Pci Dermatological Diseases Viral Vector Nucleic Acid Therapeutics Delivery Technology Photochemical Internalization

---

Home Page: www.pcibiotech.com

UllernchaussEen 64
Oslo, 0379
Norway
Phone: 47 67 11 54 00

---

Officers

Exchange: F

Country: DE : Germany

Currency: Euro (€)